CN110559284A - 一种增加血液碱性、溶解含酯及脂沉积物的方法及应用 - Google Patents
一种增加血液碱性、溶解含酯及脂沉积物的方法及应用 Download PDFInfo
- Publication number
- CN110559284A CN110559284A CN201810633126.0A CN201810633126A CN110559284A CN 110559284 A CN110559284 A CN 110559284A CN 201810633126 A CN201810633126 A CN 201810633126A CN 110559284 A CN110559284 A CN 110559284A
- Authority
- CN
- China
- Prior art keywords
- formate
- oxalate
- blood
- alkalinity
- increasing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 47
- 239000008280 blood Substances 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims abstract description 33
- 150000002148 esters Chemical class 0.000 title claims abstract description 18
- 239000013049 sediment Substances 0.000 title claims abstract description 17
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims abstract description 60
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 53
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims abstract description 39
- 229940039748 oxalate Drugs 0.000 claims abstract description 33
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 25
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 17
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 16
- 239000004280 Sodium formate Substances 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical group [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 claims abstract description 14
- 235000019254 sodium formate Nutrition 0.000 claims abstract description 14
- 206010029148 Nephrolithiasis Diseases 0.000 claims abstract description 13
- 230000002265 prevention Effects 0.000 claims abstract description 12
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical group [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 claims abstract description 12
- 229940039790 sodium oxalate Drugs 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 206010020772 Hypertension Diseases 0.000 claims abstract description 9
- 230000002378 acidificating effect Effects 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 8
- 230000008021 deposition Effects 0.000 claims abstract description 6
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 claims abstract description 4
- WFIZEGIEIOHZCP-UHFFFAOYSA-M potassium formate Chemical compound [K+].[O-]C=O WFIZEGIEIOHZCP-UHFFFAOYSA-M 0.000 claims abstract description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 19
- 210000002700 urine Anatomy 0.000 claims description 18
- 235000013361 beverage Nutrition 0.000 claims description 13
- 208000000913 Kidney Calculi Diseases 0.000 claims description 12
- 201000001883 cholelithiasis Diseases 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 12
- 206010010774 Constipation Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 235000006408 oxalic acid Nutrition 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 6
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 5
- 229960003067 cystine Drugs 0.000 claims description 5
- 230000002792 vascular Effects 0.000 claims description 5
- MXZRMHIULZDAKC-UHFFFAOYSA-L ammonium magnesium phosphate Chemical compound [NH4+].[Mg+2].[O-]P([O-])([O-])=O MXZRMHIULZDAKC-UHFFFAOYSA-L 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 150000003891 oxalate salts Chemical class 0.000 claims description 4
- 229910052567 struvite Inorganic materials 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 150000004675 formic acid derivatives Chemical class 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 206010053648 Vascular occlusion Diseases 0.000 claims description 2
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000001130 gallstones Diseases 0.000 abstract description 11
- 210000004204 blood vessel Anatomy 0.000 abstract description 8
- 210000000232 gallbladder Anatomy 0.000 abstract description 4
- 230000029142 excretion Effects 0.000 abstract description 2
- 238000006386 neutralization reaction Methods 0.000 abstract description 2
- 210000005084 renal tissue Anatomy 0.000 abstract description 2
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 14
- 229940116269 uric acid Drugs 0.000 description 14
- 230000036772 blood pressure Effects 0.000 description 8
- 108090001030 Lipoproteins Proteins 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 150000001840 cholesterol esters Chemical class 0.000 description 6
- 239000004575 stone Substances 0.000 description 6
- 201000005569 Gout Diseases 0.000 description 5
- 210000000941 bile Anatomy 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 208000037157 Azotemia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010046337 Urate nephropathy Diseases 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000002660 insulin-secreting cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021333 Ileus paralytic Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010065560 Mesenteric arteriosclerosis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 201000007620 paralytic ileus Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- -1 phospholipid lipids Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 201000011303 renal artery atheroma Diseases 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明的一种增加血液碱性、溶解含酯及脂沉积物的方法及应用，该方法包括利用甲酸盐、草酸盐增加血液碱性，达到避免高血尿酸和溶解含酯及脂沉积物的效果；所述甲酸盐为甲酸钠、甲酸钾，所述草酸盐为草酸钠、草酸钾；涉及血液中高尿酸的中和，促进其清除排泄，缓解或解决高尿酸血症的问题，解决含胆固醇物质以及其它酸性物质在血管中、胆囊、肾组织中的沉积形成动脉粥样硬化、高血压、胆结石、肾结石的等疾病的预防和治疗领域问题。
Description
技术领域
本发明涉及一种增加血液碱性、溶解含酯及脂沉积物的方法及应用，涉及高尿酸血症、动脉粥样硬化、高血压、胆结石、肾结石等疾病的预防和治疗领域。
背景技术
不管什么原因所致，尿液中的尿酸高，则血液中才会相应有高尿酸而出现高尿酸血症。而高尿酸血症的并发症有如痛风形关节炎至关节变形；痛风性肾病、尿酸结石至尿毒症；刺激血管壁导致动脉粥样硬化，加重冠心病和高血压；损伤胰腺B细胞诱发或加重糖尿病。
动脉粥样硬化常导致血栓形成、供血障碍等，是冠心病、脑梗死、外周血管病的主要原因。脂质代谢障碍为动脉粥样硬化的病变基础，其特点是受累动脉病变从内膜开始，一般先有脂质和复合糖类积聚、出血及血栓形成，进而纤维组织增生及钙质沉着，并有动脉中层的逐渐蜕变和钙化，导致动脉壁增厚变硬、血管腔狭窄。
冠状动脉粥样硬化者，若管径狭窄达75％以上，则可发生心绞痛、心肌梗死、心律失常，甚至猝死；脑动脉粥样硬化可引起脑缺血、脑萎缩，或造成脑血管破裂出血；肾动脉粥样硬化常引起夜尿、顽固性高血压、严重者可有肾功能不全；肠系膜动脉粥样硬化可表现为饱餐后腹痛、消化不良、便秘等，严重时肠壁坏死可引起便血、麻痹性肠梗阻等症状；下肢动脉粥样硬化引起血管腔严重狭窄者可出现间歇性跛行、足背动脉搏动消失，严重者甚至可发生坏疽。
血浆胆固醇含量增高是引起动脉粥样硬化的主要因素。动脉粥样硬化斑块中含有大量胆固醇，是胆固醇在血管壁中堆积的结果。血浆中的脂蛋白也富含胆固醇，其中约70％与长链脂肪酸形成胆固醇酯，是血浆脂蛋白及细胞膜的重要组分。
由于胆固醇不溶于水，不能溶解于血液中，必须与蛋白质结合成脂蛋白才能携带溶解于血液，在体内运转。低密度脂蛋白容易在血管壁上沉积，造成粥样硬化，是诱发冠心病的原因。因此，实际上，胆固醇在血管中的堆积是以胆固醇酯、胆固醇脂蛋白的化学形式形成粥样硬化斑块的。另外，已知，防止胆固醇的氧化也可预防动脉粥样硬化的发生。
胆固醇也是绝大多数胆结石的主要成分，它极难溶于水，而胆汁内的胆固醇能以胆盐-磷脂微胶粒和磷脂微囊形式溶于水，胆固醇即溶于球形微胶粒内部。胆汁中胆固醇的过度饱和是胆固醇结石形成的必要条件。
肾结石是一些晶体物质(如钙、草酸、尿酸、胱氨酸等)和有机基质(如基质A、酸性粘多糖等)在肾脏的异常聚集所致。按结石的成分分类有草酸钙结石、磷酸钙结石、尿酸盐结石、磷酸铵镁结石、胱氨酸结石，其中尿酸促进草酸盐沉淀，草酸钙、尿酸盐、胱氨酸结石在尿液呈酸性时易于形成，而磷酸铵镁遇碱溶液则分解。
发明内容
本发明的增加血液碱性、溶解含酯及脂沉积物的方法是在先申请PCT/CN2018/083952的继续。在先申请中，利用甲酸钠、草酸钠经细胞或肠道内微生物糖酵解代谢或经人体内无处不在的自由基氧化反应后的产物是碱性的碳酸钠的特点，可以通过服用甲酸钠或草酸钠，或甲酸钾、草酸钾，间接增加体内碱性，中和体内酸性物质，如尿酸、谷氨酸、胃酸，达到增加尿液碱性，促进尿酸以水溶性尿酸钠方式排出体外，达到治疗痛风和减少痛风发生的作用和效果。当尿液的碱性增加时，根据人体的平衡调节，血液的碱性也一定会相应的有所增加。本发明的增加血液碱性、溶解含酯及脂沉积物的方法是利用甲酸盐、草酸盐增加尿液碱性，中和体内酸性物质的特点，将其应用进一步扩展到增加血液碱性，涉及血液中高尿酸的中和，促进其清除排泄，缓解或解决高尿酸血症的问题，解决含胆固醇物质以及其它酸性物质在血管中、胆囊、肾组织中的沉积形成动脉粥样硬化、高血压、胆结石、肾结石的问题。
本发明的增加血液碱性、溶解含酯及脂沉积物的方法的原理是基于胆固醇酯可以进行皂化反应，使胆固醇酯水解为胆固醇，因此沉积的胆固醇酯可以在碱性环境被皂化水解而溶解或混合于流动的血液中。同时，通过缓慢皂化水解含胆固醇的低密度脂蛋白沉积物、皂化水解脂蛋白以及其中所含的胆固醇酯，使它们或它们的混合物溶解于血液中，达到消除沉积在血管壁的胆固醇、各种脂蛋白等可皂化的沉积物质，从而达到疏通血管的目的和效果。另外，甲酸盐和草酸盐所具有的还原性可以防止胆固醇被氧化从而可预防动脉粥样硬化的发生。
因为胆固醇也是绝大多数胆结石的主要成分，胆汁内的胆固醇以胆盐-磷脂微胶粒和磷脂微囊形式存在于球形微胶粒内部。根据本发明的增加血液碱性、溶解含酯及脂沉积物的方法，沉积的磷脂可以在碱性环境下被缓慢皂化溶解，分解释放胆固醇进入液体胆汁，达到逐步消解胆结石的目的和效果。
同理，根据本发明的增加血液碱性、溶解含酯及脂沉积物的方法，肾结石中沉积的酸性有机基质和晶体物质，当尿液的pH增加时或偏向碱性时，打破了尿液原来的酸碱平衡，使各种沉积物质发生皂化溶解反应或偏碱性环境下的溶解反应，使各种肾结石向溶解方向进行反应。
根据本发明的一些具体实施方案，本发明的一种增加血液碱性、溶解含酯及脂沉积物的方法中，该方法包括利用甲酸盐、草酸盐增加血液碱性，达到避免高血尿酸和溶解含酯及脂沉积物的效果；所述甲酸盐为甲酸钠、甲酸钾，所述草酸盐为草酸钠、草酸钾。
根据本发明的一些具体实施方案，本发明的方法中，通过利用甲酸盐、草酸盐增加血液的碱性进而预防和治疗高尿酸血症相关的疾病。
根据本发明的一些具体实施方案，本发明的方法中，通过利用甲酸盐、草酸盐增加血液的碱性以及其还原性进而治疗与血管粥样硬化相关的疾病。
根据本发明的一些具体实施方案，本发明的方法中，通过利用甲酸盐、草酸盐增加血液的碱性以及其还原性进而治疗因血管堵塞而造成的高血压疾病。
根据本发明的一些具体实施方案，本发明的方法中，通过利用甲酸盐、草酸盐增加血液的碱性进而治疗因含胆固醇物质及脂质沉积而造成的胆结石疾病。
根据本发明的一些具体实施方案，本发明的方法中，通过利用甲酸盐、草酸盐增加尿液和血液的碱性进而治疗因含酸性基质及草酸盐、尿酸盐、胱氨酸盐、磷酸铵镁、磷酸钙结晶的沉积而造成的肾结石疾病。
另一方面，本发明还提供了在制备通过增加血液碱性以及还原性以预防和/或治疗高尿酸血症相关的以及血管粥样硬化相关的疾病的药物或饮料或食品中的应用，所述方法包括但不限于利用甲酸盐、草酸盐的单独或组合使用；最优地，选择不影响人体内草酸平衡的甲酸盐。利用甲酸盐及草酸盐无毒害的特点，可以将甲酸盐或草酸盐加入到各种饮料或食物中，因此可以作为一种新的饮料或食品产品，以达到日常对相关疾病的预防和治疗的效果(下同)。
另一方面，本发明还提供了在制备通过增加血液碱性以预防和/或治疗胆结石疾病的药物或饮料或食品中的应用，所述方法包括但不限于利用甲酸盐、草酸盐的单独或组合使用；最优地，选择不影响人体内草酸平衡的甲酸盐。
另一方面，本发明还提供了在制备通过增加尿液和血液碱性以预防和/或治疗肾结石疾病的药物或饮料或食品中的应用，所述方法包括但不限于利用甲酸盐、草酸盐的单独或组合使用；最优地，选择不影响人体内草酸平衡的甲酸盐。
另一方面，本发明还提供了在制备预防和/或治疗便秘的药物或饮料或食品中的应用，所述方法包括但不限于利用甲酸盐、草酸盐的单独或组合使用；最优地，选择不影响人体内草酸平衡的甲酸盐。这种可以预防或治疗便秘，或可治疗某些患者的便秘的现象，说明了通过改善体内的酸碱平衡，或肠道菌群的改变，或未知的原因，直接或间接地达到了可以预防及治疗或部分治疗便秘的效果。
具体实施方式
实施例1
业已经12位痛风病人验证，其中严重有关节肿大的患者一位，在服用甲酸钠每天2克一个月后，经医院尿检，尿液的pH值达到8。其余11人，其中一人患有后天型糖尿病，按每天甲酸钠1克或草酸钠0.5克服用，一个月后对比医检，尿酸值从最高的480mmol降低到450mmol，平均可降低30mmol。回顾总结利用甲酸钠或草酸钠治疗癌症病人的医检报告，也可以发现，病人的尿酸水平都约降低30-50mmol，如从231降低到202，从386降低到321mmol。这些事实说明，甲酸钠、草酸钠可以降低尿液中尿酸浓度，增加尿液的pH值，即增加尿液的碱性，特别地，有助于糖尿病患者克服尿酸高引起的不适和并发症。根据人体是一个互相平衡的整体的原理，血液中的尿酸含量降低，血液的碱性也会相应的增加，因此可以减少高尿酸血症的发生，减少高尿酸血症的并发症如痛风形关节炎至关节变形；痛风性肾病、尿酸结石至尿毒症；刺激血管壁导致动脉粥样硬化，加重冠心病和高血压；损伤胰腺B细胞诱发或加重糖尿病。因此，特别地，解决尿酸高的问题，有助于糖尿病的预防和治疗。
根据这一发现，选择了8位高血压患者，其中2位临界状态的患者尚未服用降压药。服用甲酸钠每天1克，或草酸钠每天0.5克一个月后，未服用降压药的患者的血压从140/105降低到105/75，145/105降低到105/70。另外6位患者的血压都在服用降压药物降压后的基础上进一步的降低了血压，从130-140/80-100降低到～110/～70。其中一位已经服用10年以上降压药的患者的血压降低到105/60，后遵从医生建议，开始减半服用此前的降压药，使血压恢复到110/70；目前期待能够逐步彻底停用降压药物。
血压的降低应该是因为血管的疏通减少了血流的阻力的缘故，其疏通的机制应该是动脉粥样硬化斑块中含胆固醇的脂质等的疏松和溶解。
利用甲酸盐及草酸盐无毒害的特点，可以将甲酸盐或草酸盐加入到各种饮料或食物中，因此可以作为一种新的饮料或食品产品，以达到方便日常对相关疾病的预防和治疗的效果(下同)。添加量可以根据不同的口感要求，在各种饮料中包括在纯净水、矿泉水等瓶装水中添加0.5-5重量％，或各种加工的食品中添加0.5-5重量％。
实施例2
考虑到胆固醇或含胆固醇的磷脂脂质也是胆结石的成因之一，以及胆盐在碱性环境下的溶解性，预期胆结石也可以被碱性环境所缓慢消解。因此选择了2位有胆结石的患者，医检结石大小分别在1*0.8厘米和1.3*1厘米。平时时常有胆区的不适感，但一位服用甲酸钠每天1克，一位服用草酸钠每天0.5克，半个月后，即很少有胆区的不适感出现。说明了当人体尿液和血液偏向碱性时，全身器官整体也都偏向碱性状态，使胆结石在缩小的过程之中。
实施例3
考虑到碱性环境打破了尿液和血液的酸碱原本平衡，同时碱性或偏向碱性的环境可以促进肾结石酸性基质的溶解，预期肾结石也可以被碱性环境所缓慢消解。因此选择了1位有肾结石史10年以上的患者，医检有多处散在结石，最大结石大小约为0.5*0.3厘米。平时时常有肾区的疼痛不适感，但服用甲酸钠每天1克，半个月后，即很少有肾区的不适感出现。说明了胆结石应该是在缩小的过程之中。
实施例4
在众多的肿瘤患者循环服用甲酸钠、草酸钠以及其它还原剂的治疗过程中，均发现有便秘问题的患者，随着治疗的进行，其便秘问题即得到缓解或解决。因此专门选择便秘患者6人，严重者3天才能解便一次，一般一次解便时间通常需要半小时左右。其中3人服用甲酸钠每天1克，另外三人每天服用草酸钠0.5克，一般服用的第二或第三天即出现解便迅速和顺畅的现象。虽然其治疗的机制机理不能明确确定，有各种的可能的机制机理，如肠道菌群结构的改变，或酸性体质的修正。
以上所述，仅是本发明的较佳实施例，任何所属技术领域中具有通常知识者，在不脱离本发明所提技术特征的范围内，利用本发明所揭示技术内容所做出局部更动或修饰的等效实施例，并且未脱离本发明的技术特征内容，均仍属于本发明技术特征的范围内。
Claims (10)
1.一种增加血液碱性、溶解含酯及脂沉积物的方法，该方法包括利用甲酸盐、草酸盐增加血液碱性，达到避免高血尿酸和溶解含酯及脂沉积物的效果；所述甲酸盐为甲酸钠、甲酸钾，所述草酸盐为草酸钠、草酸钾。
2.根据权利要求1所述的方法，其中，通过利用甲酸盐、草酸盐增加血液的碱性进而预防和治疗高尿酸血症相关的疾病。
3.根据权利要求1所述的方法，其中，通过利用甲酸盐、草酸盐增加血液的碱性以及其还原性进而治疗与血管粥样硬化相关的疾病。
4.根据权利要求1或3所述的方法，其中，通过利用甲酸盐、草酸盐增加血液的碱性以及其还原性进而治疗因血管堵塞而造成的高血压疾病。
5.根据权利要求1所述的方法，其中，通过利用甲酸盐、草酸盐增加血液的碱性进而治疗因含胆固醇物质及脂质沉积而造成的胆结石疾病。
6.根据权利要求1所述的方法，其中，通过利用甲酸盐、草酸盐增加尿液和血液的碱性进而治疗因含酸性基质及草酸盐、尿酸盐、胱氨酸盐、磷酸铵镁、磷酸钙结晶的沉积而造成的肾结石疾病。
7.一种增加血液碱性、溶解含酯及脂沉积物的方法在制备通过增加血液碱性以及还原性以预防和/或治疗高尿酸血症相关的以及血管粥样硬化相关的疾病的药物或饮料或食品中的应用，其中，所述方法包括但不限于利用甲酸盐、草酸盐的单独或组合使用；最优地，选择不影响人体内草酸平衡的甲酸盐。
8.一种增加血液碱性、溶解含酯及脂沉积物的方法在制备通过增加血液碱性以预防和/或治疗胆结石疾病的药物或饮料或食品中的应用，其中，所述方法包括但不限于利用甲酸盐、草酸盐的单独或组合使用；最优地，选择不影响人体内草酸平衡的甲酸盐。
9.一种增加血液碱性、溶解含酯及脂沉积物的方法在制备通过增加尿液和血液碱性以预防和/或治疗肾结石疾病的药物或饮料或食品中的应用，其中，所述方法包括但不限于利用甲酸盐、草酸盐的单独或组合使用；最优地，选择不影响人体内草酸平衡的甲酸盐。
10.一种增加血液碱性、溶解含酯及脂沉积物的方法在制备预防和/或治疗便秘的药物或饮料或食品中的应用，其中，所述方法包括但不限于利用甲酸盐、草酸盐的单独或组合使用；最优地，选择不影响人体内草酸平衡的甲酸盐。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810633126.0A CN110559284A (zh) | 2018-06-06 | 2018-06-06 | 一种增加血液碱性、溶解含酯及脂沉积物的方法及应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810633126.0A CN110559284A (zh) | 2018-06-06 | 2018-06-06 | 一种增加血液碱性、溶解含酯及脂沉积物的方法及应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110559284A true CN110559284A (zh) | 2019-12-13 |
Family
ID=68772377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810633126.0A Pending CN110559284A (zh) | 2018-06-06 | 2018-06-06 | 一种增加血液碱性、溶解含酯及脂沉积物的方法及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110559284A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021155795A1 (zh) * | 2020-02-03 | 2021-08-12 | 秦才东 | 一种药物组合物及其应用 |
-
2018
- 2018-06-06 CN CN201810633126.0A patent/CN110559284A/zh active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021155795A1 (zh) * | 2020-02-03 | 2021-08-12 | 秦才东 | 一种药物组合物及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ROGERS et al. | Primary Hypertrophy and Hyperplasia of the Parathyroid Glands Associated with Duodenal Ulcer: Report of an Additional Case, with Special Reference to Metabolic, Gastrointestinal and Vascular Manifestations | |
| Sobata et al. | Cerebrovascular disorders associated with von Recklinghausen's neurofibromatosis: a case report | |
| CN110559284A (zh) | 一种增加血液碱性、溶解含酯及脂沉积物的方法及应用 | |
| Silbert et al. | Monckeberg's arteriosclerosis | |
| WO2001034143A1 (fr) | Agents de prevention ou de traitement de maladies inflammatoires de l'intestin | |
| Zarling et al. | Bezoar therapy: complication using Adolph's meat tenderizer and alternatives from literature review | |
| Moolenaar et al. | Ischemic colitis and acalculous necrotizing cholecystitis as rare manifestations of cholesterol emboli in the same patient. | |
| Odoemene et al. | Ureterolithiasis: management in an environment with limited facilities | |
| Laugier et al. | Chronic obstructive pancreatitis after healing of a necrotic pseudocyst | |
| Chibishev et al. | Ingestion of caustic substances in adults: a review article | |
| JP2008019221A (ja) | 動脈瘤の予防及び／又は治療薬 | |
| Alsumait et al. | Pancreaticocolonic fistula: a complication of pancreatitis. | |
| Matesic et al. | Acute pancreatitis due to hereditary angioedema | |
| PASTERNACK | Calcareous pancreatitis; report of three cases with autopsies | |
| Nakajima et al. | Spontaneous disappearance and reappearance of a ruptured cerebral aneurysm: one case found in a group of 33 consecutive patients with subarachnoid hemorrhage who underwent repeat angiography | |
| Popper et al. | Pancreas function tests | |
| Eastwood et al. | The Management of Patients with Diarrhoea Resulting from Ileal Dysfunction | |
| Mohammed et al. | The Effectiveness of Laser in Treatment of Haemorrhoids | |
| Geetha et al. | Effects and causes of Lithiasis | |
| Londhe et al. | Study on the Anti-lithogenic effect of Tablet Bigol and Shashwat Ghrita in the management of Cholelithiasis (Pittashmari) | |
| Nieper–Germany | Serrapeptase (New) | |
| Gîncu et al. | Diagnosis and modern medical-surgical tactics in the treatment of biliary atresia in children | |
| Gong et al. | Docosahexaenoic acid alleviates cartilage degradation by mediating apoptosis and autophagy via JNK and p38 signaling pathways in human chondrocytes and osteoarthritis rat model | |
| Djalilovich et al. | Modern methods of therapy of acute gastroduodenal bleeding in patients with severe burns | |
| Choi et al. | Use of Olive Oil for the Treatment of a Phytobezoar: A Case Report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191213 |